InCor Hospital has received approval to begin a large scale Phase 2 Hypertension Study using Avatr. The study will evaluate benefits of Avatr technology to support patient engagement, improved quallity-of-life, improved clinical outcomes and cost savings.
The Inavya team has been co-developing a novel Avatr-in-the-Ward to modernise nurse call systems for patients in the hospital. This initiative is an NIHR portfolio project for the NHS.
Inavya has won a government contract to deliver Avatr services with hospitals in Peru. The focus of Project EmpatIA is to improve access to healthcare for citizens in Peru.
Inavya has won an 18 month Smart Award to develop an integrated cost calculator enhancement for the AVATR technology. SAVER will use real-time clinical decision-making data to support optimal cost savings for the NHS. Project partners include IPSOS and Imperial College Healthcare NHS Trust.
Inavya has won an SBRI contract from the NHS to deliver Project POP-60 - Post-Operative 60 Days protocol.
The project will last for 12 months, and aims to improve health outcomes and reduce costs for patients when they leave hospital. Project partners are Imperial College Healthcare and IPSOS.
Dr Peter Sahota was invited to present AVATR and the Inavya-InCor scientific approach to digital health experts at the SOCESP forum in São Paulo.
This presentation highlighted Inavya’s quality of the work done in partnership with the medical teams in Brazil, and supported by the British embassy.
AVATR was showcased by Guilherme Rabello, Innovation director at InCor Hospital, in a panel session for Hospitalar – one of the largest health care conventions in Brazil.
AVATR had its first peer reviewed publication in the Journal of Hypertension. The publication reported that AVATR “improves BP (Blood Pressure) control and adherence to antihypertensive medication and healthy lifestyle, providing a strong interaction between patients and healthcare team by distance monitoring”.
The study was conducted by InCor hospital in São Paulo, a global center of clinical excellence and one of the largest cardiac hospitals worldwide.
Inavya Ventures, The Zerbini foundation and Hospital das Clinicas in Brazil, have announced a partnership, combining their efforts to enrich AVATR-enabled digital healthcare to support patients across Brazil.
One of the three largest cardiological centres in the world in terms of volume of care and number of sub-specialities of cardiology, InCor is also considered the best cardiology hospital in Brazil and Latin America.
AVATR was featured in the Raconteur Special Report for the Time. The article highlighted the opportunities of international expansion and how digital business enables the development of smart cities, citing AVATR as an example.
Inavya and Imperial College NHS have just been awarded an Innovate UK R&D grant for Project BAMBOOS (Black Asian Minority Bespoke Outpatient Obesity Services).
Project BAMBOOS aims to develop highly personalised, contextual and culturally-sensitive outpatient services for patients at risk of CHD, diabetes and COVID-related complications. This is a significant step in AVATR’s mission to deliver personalised and culturally competent healthcare using AI.
HealthcareUK (part of Department of Health and Social Care and Department for International Trade) confirmed that AVATR will be officially announced as part of the 'First 100' UK Homegrown Digital Health firms.
As a result, AVATR will be presented in a slide deck for Government use only. Moreover, commercial officers from the Department for International Trade worldwide will promote AVATR via the embassy networks, with a view to encouraging international growth.
Inavya engineers and designers are now working collaboratively with St. Bartholomew's Hospital clinicians to co-develop AVATR services to support the rehabilitation of South Asian cardiac patients. The ultimate objective is to engage patients as partners in their healthcare.
This is a very exciting opportunity within the NHS that builds on AVATR AI capability to deliver highly personalised and contextualised healthcare in the community, in collaboration with Queen Mary University of London.
As part of our medical study in Brazil, AVATR has been deployed at São Paulo University Hospital InCor, for patients suffering from Hypertension. In the context of COVID this will reduce the burden on the medical team, who will be monitoring of the patients remotely. It will also allow them to update their patient care plan and protocols without bringing them to the hospital, reducing the risk of spreading COVID-19.
AVATR and Inavya Ventures Ltd. are now officially approved suppliers of healthcare technology to the UK Government.
This will help fast track our sale cycle in the UK on the back of the current studies initiated with our UK hospital partners.
Our first randomised medial trial is starting in the UK, focusing on patients suffering from obesity and atrial fibrillation. The patient onboarding phase has started. The study aims to demonstrate that the patient engagement provided through AVATR will help reduce health risks and improve the quality of life, freeing up time and resources for the medical teams.
Inavya Ventures and its AVATR technology have been shortlisted by SWITCH (Singapore Week of Innovation and Technology) as one of the top 10 startups helping to combat the current global pandemic. This is recognition of the impact our technology delivers for populations at risk and suffering from chronic disease – namely through remote monitoring and a macro dashboard for global analysis within large cities.